This article is more than 5 years old. Information may no longer be current.

VIDEO: MA.17R trial shows ‘clear benefit’ of extended hormonal therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Ron Bose, MD, PhD, medical oncologist at Washington University School of Medicine in St. Louis, reviews the positive results from the MA.17R trial at the ASCO Annual Meeting.

In the trial, researchers randomly assigned patients with hormone receptor–positive breast cancer to receive an additional 5 years of letrozole or placebo after the standard 5 years of therapy. Results showed extended treatment reduced the risk for recurrence by a 34% (HR = 0.66; P = .01).

“At a practical level, this trial demonstrates that there is clear benefit of extended use of an aromatase inhibitor in hormone receptor–positive breast cancer patients in whom osteoporosis or fracture risk can be controlled,” Bose said.